Watchlist Price Alert

ADMA Biologics Inc. (ADMA)

NASDAQ: ADMA · Real-Time Price · USD

20.80

-0.80 (-3.70%)

At close: Jun 13, 2025, 3:59 PM

21.50

3.37%

After-hours: Jun 13, 2025, 05:56 PM EDT

-3.70% (1D)

Bid	20.8
Market Cap	4.97B
Revenue (ttm)	459.38M
Net Income (ttm)	206.77M
EPS (ttm)	0.84
PE Ratio (ttm)	24.76
Forward PE	22
Analyst	Strong Buy

Ask	22.44
Volume	2,310,869
Avg. Volume (20D)	3,494,226
Open	21.25
Previous Close	21.60
Day's Range	20.52 - 21.51
52-Week Range	10.21 - 25.67
Beta	0.47

About ADMA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ADMA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ADMA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-10.21%

ADMA Biologics shares are trading lower after the ... Unlock content with Pro Subscription

1 month ago

+12.12%

ADMA Biologics shares are trading higher after the company announced FDA approval of its yield enhancement production process.

News

1 week ago · zacks.com

ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?

ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.

2 weeks ago · zacks.com

ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

1 month ago · seekingalpha.com

ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss

ADMA Biologics has demonstrated significant revenue growth, margin expansion, and profitability, leading to a 1,314% increase in share price since 2021. The company's Q1 performance showed a 40% YoY r...

1 month ago · zacks.com

ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?

ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025.

1 month ago · seekingalpha.com

ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossm...

1 month ago · zacks.com

Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates

Adma Biologics (ADMA) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.08 per share a year ago.

1 month ago · marketbeat.com

3 Mid-Cap Medical Stocks Outperforming the Market

While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotec...

1 month ago · zacks.com

Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.